BioAmber Inc. (BIOA):
BioAmber Inc. (BIOA) ended its previous trading session at $0.65 with the Gain of 14.51%. The company’s market cap is $36.93 Million, and the average volume is $1.92 Million. The 52-Week High range of the stock is $6.5, while the 52-week low range is $0.32. The Price to Sales (P/S) of the stock is 3.52, while P/B (Price to Book) stands at 0.34. When we look at the Volatility of the company, Week Volatility is at 11.14% whereas Month Volatility is at 9.76%.
For the ongoing Fiscal Quarter, 1 analysts have an average earnings forecast of $-0.06 per share. According to the Analysts, the Low Earnings estimate for the current quarter is $-0.06, while the High earnings estimate is $-0.06.Comparatively, EPS for the same quarter last year was $0.
According to 1 analysts, the Average Revenue Estimate for the current Fiscal quarter is $9.3 Million and the Low Revenue estimate is $9.3 Million, while the High Revenue estimate is $9.3 Million.
BioAmber Inc. (BIOA) analysts on average have given a price target of $6.75 on BIOA stock.
According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 2 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.
Infinity Pharmaceuticals, Inc. (INFI):
Infinity Pharmaceuticals, Inc. (INFI) shares Jumped 14.29% and ended the day at $2.4. Its 52-week high and low range is between $3.84 and $0.84. The company’s outstanding shares are 65.21 Million. The volume of the company in the last trading session was 4.35 Million. The stock has a market cap of 156.5 Million. The Stock shows P/E value of 0 and Forward P/E of 0.
According to Finviz reported data, The SMA20 of the stock is at 40.93%, SMA50 is 78.25 percent, while SMA200 is 27.44%. The stock is currently has its Return on Assets (ROA) value of -59.2 Percent. The Return on Investment and Return on Equity (ROE) values are -30.3 percent and -88.1 percent, respectively.
The company’s ATR (Average True Range) is 0.36. The Weekly Volatility is 22.64% and the Monthly Volatility is 15.43%.
When we look at the Analyst Recommendations of the stock, the company has 2.5 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.
Infinity Pharmaceuticals, Inc. (INFI) analysts on average have given a price target of $6.75 on INFI stock.
Infinity Pharmaceuticals, Inc.’s Average Earnings Estimate for the current quarter is $-0.2, according to consensus of 4 analysts. The low EPS estimate is $-0.22, while the high EPS estimate is $-0.15.
Average Revenue Estimate of the company for the current Fiscal Quarter is $14.7 Million, according to consensus of 4 analysts. The higher end of the revenue estimate is $58.8 Million and the lower end is $0.